The acute effect of dexfenfluramine on resting metabolic rate and postprandial thermogenesis in obese subjects: a double-blind placebo-controlled study. 1993

L Scalfi, and E D'Arrigo, and V Carandente, and A Coltorti, and F Contaldo
Institute of Internal Medicine and Metabolic Diseases, Medical School, Federico II University, Naples, Italy.

The effects of dexfenfluramine (dFE: 30 mg per os) on energy expenditure were evaluated in seven young obese male subjects (mean +/- s.d.: age 30.9 +/- 6.1 years; BMI 39.8 +/- 4.4 kg/m2). Each subject was submitted, on a double-blind protocol and by random order, to four tests in which dFE or placebo (Pla) were administered either in the fasting state or in combination with a mixed test meal. Energy expenditure was measured by indirect calorimetry for 60 min before (BMR) and from 90 to 330 min after dFE or Pla. In those cases where the protocol required it, a mixed test meal (5 MJ, 1200 kcal; percentage of protein, carbohydrate and fat: 15, 55, and 30 respectively) was eaten 120 min after dFE or Pla. In the fasting state resting metabolic rate increased after dFE (mean +/- s.d.: 0.49 +/- 0.20 kJ/min) but not after Pla (-0.04 +/- 0.16 kJ/min) in comparison to BMR, the difference between the two tests being highly significant (P < 0.01). Post-prandial thermogenesis (over 3h) was also significantly higher after dFE than after Pla (232 +/- 85 kJ vs. 181 +/- 73 kJ; P < 0.025). On the other hand, dFE did not affect respiratory quotient (RQ), either in the fasting state or in the fed state. These results show that in obese subjects dFE increases energy expenditure in the post-absorptive state, as well as after the ingestion of food.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D001833 Body Temperature Regulation The processes of heating and cooling that an organism uses to control its temperature. Heat Loss,Thermoregulation,Regulation, Body Temperature,Temperature Regulation, Body,Body Temperature Regulations,Heat Losses,Loss, Heat,Losses, Heat,Regulations, Body Temperature,Temperature Regulations, Body,Thermoregulations
D002153 Calorimetry, Indirect Calculation of the energy expenditure in the form of heat production of the whole body or individual organs based on respiratory gas exchange. Calorimetry, Respiration,Calorimetries, Indirect,Calorimetries, Respiration,Indirect Calorimetries,Indirect Calorimetry,Respiration Calorimetries,Respiration Calorimetry
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004734 Energy Metabolism The chemical reactions involved in the production and utilization of various forms of energy in cells. Bioenergetics,Energy Expenditure,Bioenergetic,Energy Expenditures,Energy Metabolisms,Expenditure, Energy,Expenditures, Energy,Metabolism, Energy,Metabolisms, Energy
D005215 Fasting Abstaining from FOOD. Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger
D005277 Fenfluramine A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release. Fintepla,Fenfluramine Hydrochloride,Fenfluramine Hydrochloride, (+-)-Isomer,Fenfluramine Hydrochloride, R-Isomer,Fenfluramine, (+-)-Isomer,Fenfluramine, R-Isomer,Isomeride,Pondimin,Fenfluramine Hydrochloride, R Isomer,Fenfluramine, R Isomer,Hydrochloride, Fenfluramine

Related Publications

L Scalfi, and E D'Arrigo, and V Carandente, and A Coltorti, and F Contaldo
January 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity,
L Scalfi, and E D'Arrigo, and V Carandente, and A Coltorti, and F Contaldo
February 1995, Metabolism: clinical and experimental,
L Scalfi, and E D'Arrigo, and V Carandente, and A Coltorti, and F Contaldo
August 1988, The American journal of clinical nutrition,
L Scalfi, and E D'Arrigo, and V Carandente, and A Coltorti, and F Contaldo
July 1990, International journal of obesity,
L Scalfi, and E D'Arrigo, and V Carandente, and A Coltorti, and F Contaldo
September 2001, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine],
L Scalfi, and E D'Arrigo, and V Carandente, and A Coltorti, and F Contaldo
May 1988, The American journal of clinical nutrition,
L Scalfi, and E D'Arrigo, and V Carandente, and A Coltorti, and F Contaldo
July 1990, International journal of obesity,
L Scalfi, and E D'Arrigo, and V Carandente, and A Coltorti, and F Contaldo
November 2021, Journal of medicinal food,
L Scalfi, and E D'Arrigo, and V Carandente, and A Coltorti, and F Contaldo
February 2002, Nutritional neuroscience,
L Scalfi, and E D'Arrigo, and V Carandente, and A Coltorti, and F Contaldo
August 1993, European journal of clinical nutrition,
Copied contents to your clipboard!